Rare disease companies develop diagnostics, therapies and research technologies for conditions affecting relatively small patient populations. Their work often focuses on inherited disorders, complex diagnostic pathways and diseases with limited or no existing treatment options.
This category includes companies working on:
Browse 141 UK rare disease companies below.
Tissue-targeted gene and RNA delivery platforms for rare and neurological disease
Dawn Therapeutics is a pre-clinical biotechnology company developing precision delivery platforms for genetic medicines targeting the central nervous system, cartilage, and bone. Its transferrin receptor-guided system is designed to cross the blood-brain barrier and deliver RNA or DNA payloads to neuronal tissues,…
Exosome-delivered gene editing therapies for neurodegenerative diseases
Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies for rare, genetically driven neurodegenerative diseases. Its proprietary platform uses engineered exosomes to deliver CRISPR-based gene editors across the blood-brain barrier, enabling targeted genetic intervention in the…
European specialty pharma focused on gastroenterology and hepatology
Norgine is a European specialty pharmaceutical company developing, manufacturing, and commercialising medicines across gastroenterology, hepatology, and cancer supportive care. Founded in 1906 and privately owned, the company markets a portfolio of specialty pharmaceutical products and medical devices across Europe,…
Inhaled therapies for COPD and chronic respiratory diseases
Verona Pharma is a biopharmaceutical company developing and commercialising inhaled therapies for chronic respiratory diseases. Its lead product, ensifentrine, is a first-in-class dual inhibitor of PDE3 and PDE4 that combines bronchodilator and non-steroidal anti-inflammatory activity in a single inhaled compound.…
High-throughput iPSC reprogramming and stem cell drug discovery services
Oxford StemTech is a contract research company providing induced pluripotent stem cell (iPSC) reprogramming and drug discovery services using its proprietary platform. The technology enables large-scale, cost-effective generation of patient-derived iPSC lines from blood or skin samples, supporting disease modelling,…
AAV gene therapies for rare neurological diseases of childhood
BlackfinBio is a biotechnology company developing AAV-based gene therapies for rare neurodegenerative diseases of the central nervous system, with an initial focus on children. Its lead programme is a one-time gene therapy administered directly to the brain, designed to treat a group of ultra-rare dopamine deficiency…
Lentiviral gene therapy developer for tumours and rare diseases
Santo Therapeutics develops in vivo lentiviral gene therapies for cancer and rare genetic disorders. Its proprietary vector platform supports programmes including ST002, an NF2 gene-replacement therapy for NF2-related schwannomatosis. The company announced the start of an investigator-initiated clinical trial of ST002…
Gene therapy platform targeting paediatric solid tumours
Kindling Bio is a biotechnology company developing a gene therapy platform designed specifically for childhood cancers. The platform engineers a biological signal that renders paediatric solid tumours visible to the immune system, enabling immune-mediated destruction across multiple tumour types from a single…
AAV gene therapy targeting the seizure focus in refractory epilepsy
Focalis Bio is a biotechnology company developing gene therapies for focal refractory epilepsy, a condition in which seizures arise from a specific brain region and do not respond to antiseizure medicines. Its lead programme, EPY201, is an AAV9-based gene therapy delivered locally via catheter directly to the…
Rare and serious disease therapeutics with Cambridge R&D hub
Insmed is a US biopharmaceutical company with commercial-stage and late-pipeline products spanning respiratory, inflammatory and rare neurological diseases. Its Cambridge facility at Babraham Research Campus, established through the 2023 acquisition of Adrestia, leads drug discovery using the company's synthetic…
Multiplexed LC-MS proteomics for biomarker development and clinical trials
Inoviv is a bioanalytical contract research company providing multiplexed, quantitative LC-MS targeted proteomics services to pharmaceutical and biotech clients. Its platform supports biomarker discovery, patient stratification, companion diagnostic development, and treatment efficacy monitoring across clinical and…
Small molecule therapies for keratin-related skin disorders
Mariposa Therapeutics is a Welsh preclinical biopharma company developing disease-modifying treatments for epidermolysis bullosa simplex and other keratin-related skin disorders. Its lead compound, MP5219, is a synthetic analogue of ajoene that activates surrogate keratin expression to compensate for the underlying…
Full-service clinical and commercial solutions across the drug development lifecycle
Syneos Health is a global biopharmaceutical solutions organisation providing integrated clinical and commercial services to pharmaceutical, biotechnology and medical device companies. Its Clinical Solutions offering spans Phase I to IV development, including clinical monitoring, patient recruitment, data management…
Global biopharma with UK R&D hub in Hertfordshire
Roche Products is the UK pharmaceutical arm of F. Hoffmann-La Roche, headquartered at Welwyn Garden City in Hertfordshire. The site employs over 1,900 people and serves as a primary hub for early-stage drug discovery, clinical development, computational sciences, and commercial operations. The UK operation contributes…
Circadian hormone therapeutics for rare endocrine conditions
Neurocrine UK is the European operations of Neurocrine Biosciences, a Cardiff-headquartered specialty pharmaceutical company developing and commercialising hormone therapeutics for rare and chronic endocrine conditions. The company's scientific approach centres on circadian-based formulation technology, designed to…
AAV gene therapies for rare and neurological diseases
Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus-based gene therapies for serious chronic diseases. Its lead programme is a Phase I/II gene therapy for Gaucher disease type 1, a rare lysosomal storage disorder. Further pipeline candidates target GBA1 Parkinson's disease and…
Ex vivo haematopoietic stem cell gene therapies for rare genetic diseases
Orchard Therapeutics is a gene therapy company developing ex vivo haematopoietic stem cell therapies for rare genetic diseases, primarily severe neurometabolic and immunological disorders in children. Its platform modifies a patient's own stem cells with a functional copy of the defective gene before reinfusion. Lead…
AAV gene therapies for neurodegenerative diseases including FTD and ALS
AviadoBio is a clinical-stage gene therapy company developing AAV-based treatments for neurodegenerative diseases. Its lead programme, AVB-101, is in a Phase 1/2 trial for frontotemporal dementia caused by GRN gene mutations, delivering a functional copy of the GRN gene via intrathalamic infusion to restore…
Nanoparticle platform for targeted genetic medicine delivery
ViaNautis is a nanomedicine company developing a polymer nanoparticle platform for the targeted intracellular delivery of genetic therapeutic payloads across difficult-to-penetrate biological barriers. The platform is designed to encapsulate a broad range of genetic cargoes and guide them to specific tissues and cell…
DNA-based gene therapy platform for intercellular therapeutic gene delivery
Bitrobius Genetics is a UK biotech developing a novel DNA-based gene therapy platform technology designed to deliver functional copies of mutated genes to cells within a target tissue or organ. Its platform is based on the principle of DNA replication and intercellular transmission, aiming to achieve broad tissue…